A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2002
10/17/2002	US20020151511 Antisense oligonucleotide modulation of human MDM2 expression
10/17/2002	US20020151501 Compounds having growth hormone releasing activity
10/17/2002	US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002	US20020151497 Inhibitors comprise sequences derived from specific regions of the Lyn-kinase
10/17/2002	US20020151493 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
10/17/2002	US20020151483 C3b/C4b complement receptor-like molecules and uses thereof
10/17/2002	US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150986 Extracellular matrix signalling molecules
10/17/2002	US20020150984 Peptides for activation and inhibition of deltaPKC
10/17/2002	US20020150980 Nucleotide sequences coding protein for use in the treatment of asthma, parkinson's, heart, hypotension, osteporosis and urogenital disorders
10/17/2002	US20020150953 Detecting modulators of muscle protein activity; obtain mixture of calcineurin and muscle protein, monitor binding, incubate with modulator, monitor adjustment in binding activity compare to control
10/17/2002	US20020150638 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	US20020150622 Controlled release of anti-arrhythmic agents
10/17/2002	US20020150574 Cancer diagnosis, therapy; Dna vaccine
10/17/2002	US20020150570 Anti-CCR2 antibodies and methods of use therefor
10/17/2002	US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002	DE10118551A1 New 2-aza-bicyclo (2.2.1) heptane derivatives, are nicotinic acetyl choline receptor ligands useful for e.g. treating schizophrenia, depression or neurodegenerative diseases
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002	DE10117823A1 New N-phenyl-oxalamide derivatives, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, angina pectoris or tumor diseases
10/17/2002	DE10117184A1 Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen Substituted imidazol [1,2-a] pyridin-3-yl-amide, and amine compounds of
10/17/2002	CA2827167A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002	CA2719162A1 Methods of treating acne
10/17/2002	CA2699611A1 Desaturase genes and uses thereof
10/17/2002	CA2698579A1 Desaturase genes and uses thereof
10/17/2002	CA2606839A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	CA2479780A1 Antisense calpain nucleotides and uses thereof
10/17/2002	CA2444024A1 Thiohydantoins and use thereof for treating diabetes
10/17/2002	CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	CA2443378A1 Methods of screening and using inhibitors of angiogenesis
10/17/2002	CA2443334A1 Protein modification and maintenance molecules
10/17/2002	CA2443223A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	CA2443108A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002	CA2443085A1 Somatostatin agonists
10/17/2002	CA2442996A1 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	CA2442986A1 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments
10/17/2002	CA2442904A1 Benzamidine derivative
10/17/2002	CA2442858A1 Zinc ionophores as anti-stress agents
10/17/2002	CA2442776A1 Antagonists of mcp-1 function and methods of use thereof
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	CA2429376A1 Mitogenic oxygenase regulators
10/16/2002	WO2001089505A1 Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
10/16/2002	WO2001079186A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors
10/16/2002	EP1249451A2 Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
10/16/2002	EP1249450A1 Benzimidazole derivatives
10/16/2002	EP1249245A1 Remedies and/or preventives for nervous system disorders
10/16/2002	EP1249238A2 Topical pharmaceutical composition comprising betanechol
10/16/2002	EP1249234A1 Method of preventing retinopathy of prematurity in a neonate
10/16/2002	EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002	EP1248847A1 Irak-4: compositions and methods of use
10/16/2002	EP1248842A1 2871 receptor, a g-protein coupled receptor and methods of use thereof
10/16/2002	EP1248837A2 Angiotensin converting enzyme homolog and its use
10/16/2002	EP1248833A1 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248791A1 Antisense modulation of caspase 3 expression
10/16/2002	EP1248787A2 Novel subtituted pyrazolo[4, 3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
10/16/2002	EP1248785A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
10/16/2002	EP1248782A1 Anticancer compound and enantiomer separation method useful for synthesizing said compound
10/16/2002	EP1248781A1 Pyrazole cyclic amp-specific pde inhibitors
10/16/2002	EP1248776A1 Semi-synthetic taxanes with antitumor and antiangiogenetic activities
10/16/2002	EP1248774A2 Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
10/16/2002	EP1248653A2 Gene therapy to promote angiogenesis and/or the treatment of heart failure
10/16/2002	EP1248651A1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
10/16/2002	EP1248638A2 Novel therapeutic use of enoxaparin
10/16/2002	EP1248624A1 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS
10/16/2002	EP1248620A1 A new use of levosimendan
10/16/2002	EP1248615A1 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
10/16/2002	EP1248607A1 Urotensin-ii receptor antagonists
10/16/2002	EP1248606A1 Use of fumaric acid derivatives for treating mitochondrial diseases
10/16/2002	EP1248517A2 Clonal propagation of primate offspring by embryo splitting
10/16/2002	EP1140065A4 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/16/2002	EP1089737B1 Levosimendan for treating pulmonary hypertension
10/16/2002	EP0991653B1 Novel compounds
10/16/2002	EP0941218B1 Antithrombotic organic nitrates
10/16/2002	EP0927161B1 Substituted cyclic amine metalloprotease inhibitors
10/16/2002	EP0910354B1 Antioxidant compounds
10/16/2002	EP0877605B1 Solid instant-release forms of administration and process for producing the same
10/16/2002	EP0763033B1 Imidazole derivatives and processes for the preparation thereof
10/16/2002	EP0741567B1 Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
10/16/2002	EP0641203B1 Pharmaceutical compositions of an imidazolyl-akenoic acid salt and their use as angiotensin ii antagonists
10/16/2002	CN1374967A Compounds for the treatment of ischemia
10/16/2002	CN1374966A 嘌呤衍生物 Purine derivatives
10/16/2002	CN1374962A 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i] purin-5-one derivatives
10/16/2002	CN1374961A Azepinoindole derivatives, the production and use thereof
10/16/2002	CN1374960A Novel integrain receptor antagonists
10/16/2002	CN1374957A Benzopyran derivative
10/16/2002	CN1374955A Oxa-and thiazole derivatives useful as antidiabetic and antibesity agents
10/16/2002	CN1374953A Aromatic nitrogenous six-membered ring compounds
10/16/2002	CN1374952A Benzimidazolone derivatives and their use as phosphodiesterase inhibibors
10/16/2002	CN1374950A Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
10/16/2002	CN1374859A 药物粉剂 Drug powder
10/16/2002	CN1374324A Giant-web bombinator angiectasis factor and its prepn and gene
10/16/2002	CN1374121A Baggod health gingko tea and its prepn
10/16/2002	CN1374082A Use of glycogen sulphofoenzyme inhibitor

1 ... 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 ... 1595